Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer

Clinical and Experimental Immunology

Volumn 109, Issue 1, 1997, Pages 157-165

  Zlotta, A R ^a   Drowart, A ^a   Huygen, K ^b   De Bruyn, J ^b   Shekarsarai, H ^a   Decock, M ^a   Pirson, M ^a   Jurion, F ^b   Palfliet, K ^b   Denis, O ^b   Mascart, F ^a   Simon, J ^a   Schulman, C C ^a   Van Vooren, J P ^a  

^a ERASME HOSPITAL   (Belgium)

^b PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

Antibody; BCG vaccine; Bladder neoplasms; Heat shock proteins; mycobacteria

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; HEAT SHOCK PROTEIN; TETANUS TOXOID; TUBERCULIN;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOTHERAPY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN PURIFICATION; TREATMENT OUTCOME;

EID: 8544278142     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4141313.x     Document Type: Article

References (37)

1. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clinics N Am 1992; 19:573-9.
2. Ratliff TL, Ritchey JK, Yuan JJ et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150:1018-23.
3. Thanhauser A, Böhle A, Schneider B et al. The induction of bacillus Calmette-Guérin activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immun Immunother 1995; 40:103-8.
4. Böhle A, Nowe Ch, Ulmer AJ et al. Elevation of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990; 144:59-64.
5. De Boer EC, De Jong WH, Van Der Meijden AP et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette - Guérin. Cancer Immunol Immunother 1991; 33:411-6.
6. De Boer EC, De Jong WH, Steerenberg PA et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 1992; 33:306-12.
7. Wiker HG, Harboe M, Bennedsen J et al. The antigens of Mycobacterium tuberculosis, H37Rv, studied by crossed immunoelectrophoresis: comparison with a reference system for Mycobacterium bovis BCG. Scand J Immunol 1988; 27:223-9.
8. Zlotta AR, Drowart A, Van Vooren JP et al. Evolution and clinical significance of the T-cell proliferative and cytokine response directed against the fibronectin-binding antigen 85 complex of bacillus Calmette-Guérin (BCG) during intravesical treatment of superficial bladder cancer. J Urol 1997; 157:492-8.
9. Young RA, Elliot TJ. Stress proteins, infection and immune surveillance. Cell 1989; 59:5-8.
10. Kaufmann SHE. Heat shock proteins and the immune response. Immunol Today 1990; 11:129-36.
11. Sherman MY, Goldberg AL. Heat shock in Escherichia coli alters the protein-binding properties of the chaperoning GroEL by inducing its phosphorylation. Nature 1992; 357:167-9.
12. Multhoff G, Botzler C, Wiesnet M et al. A stress-inducible 72-kDa heat-shock protein (hsp72) is expressed on the surface of human tumor cells but not on normal cells. Int J Canc 1995; 61:272-9.
13. Palladino MA, Srivastava PK, Oettgen HF et al. Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res 1987; 47:5074-9.
14. Koga T, Wand-Württenberger A, De Bruyn J et al. T cells against a bacterial heat shock protein recognize stressed macrophages. Nature (London) 1984; 245:1112-5.
15. Ferrarini M, Heltai S, Zocchi MR et al. Unusual expression and localization of heat-shock proteins in human tumor cells Int J Cancer 1942; 51:613-9.
16. Udono H, Sristava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1943; 178:1391-6.
17. Lukacs KV, Lowrie DB, Stokes RW et al. Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors. J Exp Med 1993; 178:343-8.
18. Content J, de la Cuvellerie A, De Wit L et al. The genes encoding for the antigen 85-complex of M. tuberculosis and M. bovis BCG are members of a gene family: cloning, sequence determination and genomic organization of the gene coding for the antigen 85-C. Infect Immun 1991; 59:3205-12.
19. Launois P, DeLeys R, Niang MB et al. T-cell epitope mapping of the major secreted mycobacterial antigen 85A in tuberculosis and leprosy. Infect Immun 1994; 62:3679-87.
20. Huygen K, Content J, Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med 1996; 8:893-8.
21. Closs O, Harhoe M, Axelsen NH et al. The antigens of Mycobacterium bovis strain BCG, studied by crossed immunoelectrophoresis: a reference system. Scand J Immunol 1980; 12:249-63.
22. De Bruyn J, Huygen K, Bosmans R et al. Purification, characterization and identification of a 32kDa protein antigen of Mycobacterium bovis BCG. Microb Pathogen 1987; 2:351-66.
23. De Bruyn J, Bosmans R, Turneer M et al. Purification, partial characterization, and identification of a skin-reactive protein antigen of Mycobacterium bovis BCG. Infect Immun 1987; 55:245-52.
24. Van Vooren JP, Turneer M, Yernault JC et al. A multidot immunobinding assay for the serodiagnosis of tuberculosis. Comparison with an enzyme-linked immunosorbent assay. J Immunol Methods 1988; 113:45-49.
25. Drowart A, Huygen K, De Bruyn J et al. Antibody levels to whole culture filtrate and to purified P32 during treatment of smear positive tuberculosis. Chest 1991; 100:685-7.
26. Turneer M, Van Vooren JP, Nyabenda J et al. The humoral immune response after BCG vaccination in humans: consequence for the serodiagnosis of tuberculosis. Eur Respir J 1988; 1:589-93.
27. Drowart A, Selleslaghs J, Yernault JC et al. The humoral immune response after BCG vaccination: an immunoblotting study using two purified antigens. Tubercle and Lung Dis 1992; 73:137-40.
28. Van Vooren JP, Drowart A, De Cock M et al. Humoral immune response of tuberculous patients against the three components of the Mycobacterium bovis BCG 85 complex separated by isoelectric focusing. J Clin Microbiol 1991; 29:2348-2350.
29. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996; 42:1-8.
30. De Bruyn J, Bosmans R, Nyabenda J et al. Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65 kDa) in culture filtrates of mycobacteria. J Gen Microbiol 1989; 135:79-84.
31. Handley HH, Yu J, Singh B et al. Autoantibodies to heat shock protein (hsp) 60 may be induced by Escherichia coli GroEL. Clin Exp Immunol 1996; 103:429-35.
32. Thole JE, van Schooten WC, Keulen WJ et al. Use of recombinant antigens expressed in Escherichia coli K-12 to map B-cell and T-cell epitopes on the immunodominant 65-kilodalton protein of Mycobacterium bovis BCG. Infect. Immun 1988; 56:1633-40.
33. Winters WW, Lamm DL. Antibody response to bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. Canc Res 1981; 41:2672-6.
34. Wile AG, Sparks FC, Morton DL. Monitoring immunotherapy with bacillus Calmette-Guérin by antibody titre. Cane Res 1977; 37:2251-6.
35. van der Meijden APM, Steerenberg PA, van Hoogstraaten MW et al. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother 1989; 28:287-95.
36. Hara I, Sato N, Kikuchi K et al. Immune response against BCG 65 kDa protein antigen in bladder cancer with BCG instillation therapy. Analyses carried out with the gene of this protein to develop a monoclonal antibody. Nippon Hinyokika Gakkai Zasshi 1991; 82:24-32.
37. De Reijke TM, De Boer EC, Kurth KH et al. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155:477-82.